These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 28791374)
1. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways. Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374 [TBL] [Abstract][Full Text] [Related]
2. A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways. Jia L; Jin H; Zhou J; Chen L; Lu Y; Ming Y; Yu Y BMC Complement Altern Med; 2013 Feb; 13():33. PubMed ID: 23410205 [TBL] [Abstract][Full Text] [Related]
3. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Gao Y; Foster R; Yang X; Feng Y; Shen JK; Mankin HJ; Hornicek FJ; Amiji MM; Duan Z Oncotarget; 2015 Apr; 6(11):9313-26. PubMed ID: 25823654 [TBL] [Abstract][Full Text] [Related]
4. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells. Wang H; Zhu L; Gao J; Hu Z; Lin B Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091 [TBL] [Abstract][Full Text] [Related]
5. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739 [TBL] [Abstract][Full Text] [Related]
6. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer. Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672 [TBL] [Abstract][Full Text] [Related]
7. Metformin and epithelial ovarian cancer therapeutics. Patel S; Kumar L; Singh N Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. Wahba J; Natoli M; Whilding LM; Parente-Pereira AC; Jung Y; Zona S; Lam EW; Smith JR; Maher J; Ghaem-Maghami S Cancer Immunol Immunother; 2018 Nov; 67(11):1753-1765. PubMed ID: 30167862 [TBL] [Abstract][Full Text] [Related]
9. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer. Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271 [TBL] [Abstract][Full Text] [Related]
10. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309 [TBL] [Abstract][Full Text] [Related]
11. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. Hainsworth JD; Thompson DS; Bismayer JA; Gian VG; Merritt WM; Whorf RC; Finney LH; Dudley BS Cancer Med; 2015 May; 4(5):673-81. PubMed ID: 25556916 [TBL] [Abstract][Full Text] [Related]
12. Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer. Nguyen TM; Shin IW; Lee TJ; Park J; Kim JH; Park MS; Lee EJ Gynecol Oncol; 2016 Mar; 140(3):545-53. PubMed ID: 26691219 [TBL] [Abstract][Full Text] [Related]
13. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis. Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658 [TBL] [Abstract][Full Text] [Related]
14. Bioguided Fraction and Isolation of the Antitumor Components from Zheng ZZ; Chen LH; Liu SS; Deng Y; Zheng GH; Gu Y; Ming YL Biomed Res Int; 2016; 2016():9729275. PubMed ID: 27777954 [No Abstract] [Full Text] [Related]
15. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway. Zhang C; Wang M; Shi C; Shi F; Pei C Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug. Rivard C; Geller M; Schnettler E; Saluja M; Vogel RI; Saluja A; Ramakrishnan S Gynecol Oncol; 2014 Nov; 135(2):318-24. PubMed ID: 25172764 [TBL] [Abstract][Full Text] [Related]
17. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells. Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684 [TBL] [Abstract][Full Text] [Related]
18. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429. Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735 [TBL] [Abstract][Full Text] [Related]
19. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells. Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577 [TBL] [Abstract][Full Text] [Related]
20. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells. Shuang T; Wang M; Shi C; Zhou Y; Wang D FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]